About AusperBio
AusperBio is a company based in San Mateo (United States) founded in 2019 by Guofeng Cheng and Chris Yang.. AusperBio has raised $223 million across 4 funding rounds from investors including Qiming Venture Partners, Hankang Capital and Sherpa Capital. AusperBio offers products and services including Med-Oligo ASO Platform. AusperBio operates in a competitive market with competitors including Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals, among others.
- Headquarter San Mateo, United States
- Founders Guofeng Cheng, Chris Yang
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$223 M (USD)
in 4 rounds
-
Latest Funding Round
$63 M (USD), Series B
Sep 21, 2025
-
Investors
Qiming Venture Partners
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AusperBio
AusperBio offers a comprehensive portfolio of products and services, including Med-Oligo ASO Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for targeted delivery of ASO therapeutics to treat various diseases.
Funding Insights of AusperBio
AusperBio has successfully raised a total of $223M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $63 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $63.0M
-
First Round
First Round
(14 Jul 2024)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series B - AusperBio | Valuation | Qiming Venture Partners | |
| May, 2025 | Amount | Series B - AusperBio | Valuation |
investors |
|
| Dec, 2024 | Amount | Series B - AusperBio | Valuation | Hankang Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AusperBio
AusperBio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Hankang Capital and Sherpa Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward opportunities in Spain.
|
Founded Year | Domain | Location | |
|
Private equity and private debt firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AusperBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AusperBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ausperbio Comparisons
Competitors of AusperBio
AusperBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eiger BioPharmaceuticals, Aligos Therapeutics, Ascentage Pharma, Bluejay Therapeutics and Presidio Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Developer of therapies to treat hepatologic diseases and viral infections
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for infectious diseases treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule antiviral therapeutics for hepatitis C are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ausperbio
Frequently Asked Questions about AusperBio
When was AusperBio founded?
AusperBio was founded in 2019 and raised its 1st funding round 5 years after it was founded.
Where is AusperBio located?
AusperBio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Who is the current CEO of AusperBio?
Guofeng Cheng is the current CEO of AusperBio. They have also founded this company.
Is AusperBio a funded company?
AusperBio is a funded company, having raised a total of $223M across 4 funding rounds to date. The company's 1st funding round was a Series B of $73M, raised on Jul 14, 2024.
What does AusperBio do?
AusperBio was founded in 2019 in San Mateo, United States, within the biotechnology sector. Focus is placed on developing treatments for chronic hepatitis B and other major infectious diseases. A pipeline of oligonucleotide therapeutics is maintained, featuring AHB-137, which utilizes conjugation technology for targeted delivery. This approach integrates DNA replication inhibitors, HBsAg inhibitors, and immunomodulators to address disease mechanisms. Operations emphasize research and therapeutic innovation in infectious disease management.
Who are the top competitors of AusperBio?
AusperBio's top competitors include Eiger BioPharmaceuticals, Finch Therapeutics and Aligos Therapeutics.
What products or services does AusperBio offer?
AusperBio offers Med-Oligo ASO Platform.
Who are AusperBio's investors?
AusperBio has 9 investors. Key investors include Qiming Venture Partners, Hankang Capital, Sherpa Capital, CDH, and BioVenture.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.